GW Pharmaceuticals PLC- ADR (GWPH) stock was skyrocketing following a successful trial of its epilepsy drug Epidiolex.
GW Pharmaceuticals’ Epidiolex was successful in reducing seizures in patients with Dravet syndrome, a form of epilepsy, by 39% over a 14-week period in its phase 3 trial. The study included 120 patients, 60 of which were given a placebo, with the average age being 10 years old.
84% of patients in the clinical trial found that the adverse effects of taking Epidiolex were only moderate. 10 suffered from serious adverse effects and eight quite the treatment. These effects included “somnolence, diarrhea, decreased appetite, fatigue, pyrexia, vomiting, lethargy, upper respiratory tract infection and convulsion.”
Following its successful phase 3 trial for Epidiolex, GW Pharmaceuticals said that it’s looking for 150 patients to take part in a second phase trails of the drug. If more trails are successful, it’s possible that Epidiolex could be the first drug approved in the U.S. to treat Dravet syndrome.
GWPH shares were up 117% as of Monday morning.
More From InvestorPlace:
- 9 Small Caps That Will Lead the Market Back
- 5 Stocks to Buy for March
- 7 A-Rated Tech Stocks to Buy Now